The first 24h: targeting the window of opportunity for antibody-mediated protection against HIV-1 transmission

被引:9
|
作者
Lewis, George K. [1 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Div Vaccine Res, 725 West Lombard St, Baltimore, MD 21201 USA
基金
美国国家卫生研究院;
关键词
antibody-mediated protection; Fc-mediated effector function; HIV transmission; HIV-1; innate immunity; BROADLY NEUTRALIZING ANTIBODIES; HUMAN MONOCLONAL-ANTIBODIES; VAGINAL SHIV CHALLENGE; HIGH-MANNOSE PATCH; CRYO-EM STRUCTURE; RHESUS MACAQUES; NONNEUTRALIZING ANTIBODIES; EFFECTOR FUNCTION; ENVELOPE TRIMER; MUCOSAL TRANSMISSION;
D O I
10.1097/COH.0000000000000319
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewI will review evidence that antibodies protect against HIV-1 transmission in a short window of opportunity, involving neutralization, Fc-mediated effector function, or both.Recent findingsThe last decade witnessed a dramatic progress in the understanding of antibody-mediated protection against HIV-1, including active and passive immunization studies in nonhuman primates; association between reduced infection risk and the specificities and function of antibodies in the RV144 clinical trial; identification of potent, broadly neutralizing antibodies; high-resolution structural studies of the HIV-1 envelope trimer; and an increasing appreciation that Fc-mediated effector function is critical to protection against transmission for neutralizing and nonneutralizing antibodies. Less information is known about how antibodies protect in situ, except that they must do in the first 24h after exposure. New evidence suggests that antibodies protect in an acute innate immune environment involving the NXLRX1 inflammasome and transforming growth factor beta (TGF-) that favors infection and rapid dissemination of CCR6(+)ROR(+) Th17 cells.SummaryThese recent findings set the stage for understanding how antibodies can prevent the transmission of HIV-1. In this context, antibodies must prevent infection in an innate immune environment that strongly favors transmission. This information is key for the development of a vaccine against HIV-1.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 50 条
  • [1] Challenges of antibody-mediated protection against HIV-1
    Lewis, George K.
    [J]. EXPERT REVIEW OF VACCINES, 2010, 9 (07) : 683 - 687
  • [2] Survivors Remorse: antibody-mediated protection against HIV-1
    Lewis, George K.
    Pazgier, Marzena
    DeVico, Anthony L.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 275 (01) : 271 - 284
  • [3] Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
    Mascola, JR
    [J]. VACCINE, 2002, 20 (15) : 1922 - 1925
  • [4] Correlates of antibody-mediated protection against HIV infection
    Sattentau, Quentin
    [J]. CURRENT OPINION IN HIV AND AIDS, 2008, 3 (03) : 368 - 374
  • [5] Antibody-mediated prevention and treatment of HIV-1 infection
    Henning Gruell
    Florian Klein
    [J]. Retrovirology, 15
  • [6] Antibody-mediated prevention and treatment of HIV-1 infection
    Gruell, Henning
    Klein, Florian
    [J]. RETROVIROLOGY, 2018, 15
  • [7] Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
    Peter B. Gilbert
    Yunda Huang
    Allan C. deCamp
    Shelly Karuna
    Yuanyuan Zhang
    Craig A. Magaret
    Elena E. Giorgi
    Bette Korber
    Paul T. Edlefsen
    Raabya Rossenkhan
    Michal Juraska
    Erika Rudnicki
    Nidhi Kochar
    Ying Huang
    Lindsay N. Carpp
    Dan H. Barouch
    Nonhlanhla N. Mkhize
    Tandile Hermanus
    Prudence Kgagudi
    Valerie Bekker
    Haajira Kaldine
    Rutendo E. Mapengo
    Amanda Eaton
    Elize Domin
    Carley West
    Wenhong Feng
    Haili Tang
    Kelly E. Seaton
    Jack Heptinstall
    Caroline Brackett
    Kelvin Chiong
    Georgia D. Tomaras
    Philip Andrew
    Bryan T. Mayer
    Daniel B. Reeves
    Magdalena E. Sobieszczyk
    Nigel Garrett
    Jorge Sanchez
    Cynthia Gay
    Joseph Makhema
    Carolyn Williamson
    James I. Mullins
    John Hural
    Myron S. Cohen
    Lawrence Corey
    David C. Montefiori
    Lynn Morris
    [J]. Nature Medicine, 2022, 28 : 1924 - 1932
  • [8] Antibody-mediated control of HIV-1 infection through an alternative pathway
    French, Martyn A.
    [J]. AIDS, 2019, 33 (13) : 1961 - 1966
  • [9] Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
    Gilbert, Peter B.
    Huang, Yunda
    deCamp, Allan C.
    Karuna, Shelly
    Zhang, Yuanyuan
    Magaret, Craig A.
    Giorgi, Elena E.
    Korber, Bette
    Edlefsen, Paul T.
    Rossenkhan, Raabya
    Juraska, Michal
    Rudnicki, Erika
    Kochar, Nidhi
    Huang, Ying
    Carpp, Lindsay N.
    Barouch, Dan H.
    Mkhize, Nonhlanhla N.
    Hermanus, Tandile
    Kgagudi, Prudence
    Bekker, Valerie
    Kaldine, Haajira
    Mapengo, Rutendo E.
    Eaton, Amanda
    Domin, Elize
    West, Carley
    Feng, Wenhong
    Tang, Haili
    Seaton, Kelly E.
    Heptinstall, Jack
    Brackett, Caroline
    Chiong, Kelvin
    Tomaras, Georgia D.
    Andrew, Philip
    Mayer, Bryan T.
    Reeves, Daniel B.
    Sobieszczyk, Magdalena E.
    Garrett, Nigel
    Sanchez, Jorge
    Gay, Cynthia
    Makhema, Joseph
    Williamson, Carolyn
    Mullins, James I.
    Hural, John
    Cohen, Myron S.
    Corey, Lawrence
    Montefiori, David C.
    Morris, Lynn
    [J]. NATURE MEDICINE, 2022, 28 (09) : 1924 - +
  • [10] Monomac-1 as a Model to Study Antibody-Mediated HIV-1 Inhibition
    Fischetti, L.
    Shattock, R. J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 48 - 48